Strong sales growth for Elscint's magnetic resonance imaging (MRI) product line
This article was originally published in Clinica
Israeli company Elscint's second-quarter sales were $75.4 million, up 14%. The company attributes this to increased sales of its MRI product line, which accounted for 30% of total sales, compared with 8% for the same period in the previous year. The company notes, however, that sales were hindered by the continued sluggish US market and a delay in the commercial supply of SeleCT, its spiral CT, which was introduced in December last year. In addition, previously agreed sales of equipment to China have been delayed.